Oxford Asset Management’s Nymox Pharmaceutical Corp NYMX Stock Holding History

Oxford Asset Management’s Portfolio NYMX Stock Details NYMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-12,503	Closed	-$33K	–	1497
2016 Q4	$33K	Buy	+12,503	New	+$38.8K	﹤0.01%	751
2016 Q1	–	Sell	-26,256	Closed	-$88K	–	926
2015 Q4	$88K	Buy	+26,256	New	+$88.1K	﹤0.01%	841
2015 Q1	–	Sell	-32,935	Closed	-$13K	–	775
2014 Q4	$13K	Buy	+32,935	New	+$70.3K	﹤0.01%	697
2013 Q3	–	Sell	-22,203	Closed	-$114K	–	929
2013 Q2	$114K	Buy	+22,203	New	+$113K	﹤0.01%	822

Other funds holding NYMX

FDCDDQ

Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return

Webster Bank Waterbury, Connecticut $1.15B AUM 23.08% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

BAS

Brown Advisory Securities Baltimore, Maryland $27.3M AUM 10.67% 1-Year Est. Return

Oxford Asset Management's NYMX Position: Q1 2017 in Review

Oxford Asset Management sold out of Nymox Pharmaceutical Corp (NYMX) in Q1 2017, closing a stake of 12,503 shares — an estimated $33K sold.

Oxford Asset Management first reported a position in NYMX in Q2 2013 and held it in 4 quarters. The position peaked at $114K in Q2 2013. 29 funds tracked by Wall St. Rank hold NYMX as of Q1 2017.

Oxford Asset Management reported no remaining Nymox Pharmaceutical Corp position as of Q1 2017 after selling out during the quarter.
Oxford Asset Management sold 12,503 Nymox Pharmaceutical Corp shares in Q1 2017, an estimated $33K.
Oxford Asset Management first reported a position in Nymox Pharmaceutical Corp in Q2 2013 and held it in 4 quarters.
Oxford Asset Management's Nymox Pharmaceutical Corp position peaked at $114K in Q2 2013.
29 funds tracked by Wall St. Rank held Nymox Pharmaceutical Corp as of Q1 2017.

Based on Oxford Asset Management's 13F filing for Q1 2017, filed 9 May 2017.